Table 5.
Reference | Cannabinoid | Dosage | Major Results | Model Used |
---|---|---|---|---|
Non-selective agonists of CB1R and CB2R associated with cholinergic pathways | ||||
Nuñez-Borque et al., 2020 [93] | NP137 | 2.5 μΜ 5 μΜ 1 mg/kg/day p.o. |
In vitro
|
In vitro experiments in immortalized lymphocytes of patients with delayed AD and in vivo experiments in TgAPP mice |
NP148 | 5 μΜ | |||
Modulator molecules that act through pathways related to the endocannabinoid system | ||||
Balleza-Tapia et al., 2018 [94] | Capsaicin (Trpv-1 agonist) | 10 μΜ |
|
In vitro experiments in Aβ-treated hippocampal cells |
Xiang et al., 2022a [96] | O-1602 (GPR-55 agonist) | 2 μg/mouse 4 μg/mouse i.c.v. |
|
In vivo experiments in Aβ1–42-treated mice |
Xiang et al., 2022b [98] |
|
In vivo experiments in STZ-treated mice | ||
Wang et al., 2022 [99] |
|
In vivo experiments in LPS-treated mice |
Abbreviations: Aβ: amyloid beta; AChE: acetylcholinesterase; AD: Alzheimer’s disease; BACE-1: β-site amyloid precursor protein cleaving enzyme; Bax: Bcl-2-associated X protein; BChE: butyrylcholinesterase; Bcl-2: B cell leukemia/lymphoma 2 protein; CAT: catalase; ERK1/2: extracellular signal-regulated kinase 1/2; GPR-55: G-protein coupled receptor 55; GSH: glutathione; i.c.v.: intracerebroventricular; LPS: lipopolysaccharide; MDA: malondialdehyde; MWM: Morris water maze; NF-κB: nuclear factor-κB; NOR: novel object recognition; p.o.: per os; PSD-95: postsynaptic density protein 95; RhoA: Ras homolog family member A; ROCK2: Rho-associated coiled-coil-containing protein kinase 2; SOD: superoxide dismutase; STZ: streptozotocin; Trpv-1: transient receptor potential cation channel subfamily V member 1; TUNEL: terminal deoxynucleotidyl transferase dUTP nick-end labeling.